TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04686344
Drug: continuous infusion of Hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion over a period of 48 hours
Study: NCT00107276
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00107276
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03962855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
Study: NCT01595087
Drug: Osteodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
Study: NCT03856866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
Study: NCT01459094
Drug: A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
Study: NCT01459094
Drug: B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
Study: NCT03952403
Drug: HLX10, an engineered anti-PD-1 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
Study: NCT04231448
Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
Study: NCT04231448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
Study: NCT03433976
Drug: spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia for planned cesarean sections
Study: NCT01881789
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
Study: NCT03965845
Drug: Telaglenestat (CB-839)
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
Study: NCT02379052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00465673
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m2 over 1 hour infusion for 21 days
Study: NCT02058979
Drug: CONTINUOUS INFUSION (Ancef)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion of ANCEF with infusion pump
Study: NCT02092181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
Study: NCT00956293
Drug: Enteric Coated Mycophenolic Acid (MPA)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
Study: NCT00956293
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
Study: NCT00956293
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Study: NCT00920556
Drug: 5.0g SRT501
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
Study: NCT01299389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
Study: NCT01220492
Drug: conventional plus MSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
Study: NCT01220492
Drug: conventional plus placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
Study: NCT02412150
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
Study: NCT02412150
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
Study: NCT02170844
Drug: Placebo of BIBR 1048 MS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741922
Drug: Acetylsalicylic morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
Study: NCT01745588
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03507127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
Study: NCT01011114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
Study: NCT05908838
Drug: Modified Banxia Xiexin Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
Study: NCT05908838
Drug: combination chemotherapy with Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination chemotherapy with Placebo granules
Study: NCT01044030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mL by mouth three times daily
Study: NCT02625181
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Analgesic drug / Opioid
Study: NCT02625181
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic drug / Opioid
Study: NCT02625181
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic drug / Opioid
Study: NCT02625181
Drug: Oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic drug / Opioid
Study: NCT02625181
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesic drug / Opioid
Study: NCT00411424
Drug: ASK8007
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT00411424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01741922
Drug: Placebos morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Study: NCT00286377
Drug: prosaptide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04364555
Drug: Placebo/Klobetasol APL oral gel 0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/active
Study: NCT04364555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/placebo
Study: NCT00606489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00741169
Drug: TMC435350
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg taken by mouth once daily for 7 days
Study: NCT00994903
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg orally, given 3-7 days pre-op and continued till 14 days post-op
Study: NCT00994903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Study: NCT01741922
Drug: Placebo evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Study: NCT01465022
Drug: Combined estrogen-progestin pill
Normalized name: estrogens, conjugated (USP) Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
Study: NCT01465022
Drug: Progestin-only pill
Normalized name: Prostin E2 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: .35 mg norethindrone once a day orally
Study: NCT02086864
Drug: lactose/sucrose granule (Individualized homeopathic medicine treatment)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
Study: NCT02086864
Drug: Placebo lactose/sucrose pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02868424
Drug: fRPE cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
Study: NCT02026011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill, matched to the active study medication in capsule size and color
Study: NCT03372161
Drug: SP-102
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT03372161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT06353477
Drug: EPs® 7630
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
Study: NCT03395496
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodentine pulpotomy agent
Study: NCT02495285
Drug: Gelofusine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495285
Drug: Gelaspan 4%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01732536
Drug: S8 Sinus Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study: NCT01836289
Drug: High-dose Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00641693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00368056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT01332214
Drug: AZD2820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection in abdomen or Thigh
Study: NCT01332214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection in abdomen or Thigh
Study: NCT03567889
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Study: NCT01281111
Drug: BG00012 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01281111
Drug: ASA matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05353686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
Study: NCT01781884
Drug: Gamma Aminobutyric Acid (GABA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
Study: NCT01781884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03323684
Drug: Ketorolac analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
Study: NCT03323684
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
Study: NCT00180037
Drug: Coenzyme Q10 Nanodispersion (Nanoquinone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00180037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890277
Drug: Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00661830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00790049
Drug: ARRY-371797, p38 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose and multiple dose, escalating
Study: NCT00790049
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00517699
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8g/m2 iv
Study: NCT04602143
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
Study: NCT03046446
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection
Study: NCT02015403
Drug: Standard Care + NAC (N -ACETYLCYSTEINE)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02015403
Drug: Standard Care (in control arm)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03500211
Drug: Lidoderm 5 % Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch after cesarean section delivery.
Study: NCT01012284
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
Study: NCT02618434
Drug: SPN-810 (18 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study: NCT02618434
Drug: SPN-810 (36 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study: NCT02618434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study: NCT00548834
Drug: CDP870
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02582827
Drug: ABI-011
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
Study: NCT00994864
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Study: NCT01265017
Drug: Estradiol, medroxyprogesterone, hydrocortisone, GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,
Study: NCT01265017
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT03679949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone